Skip to main content
. 2019 Jul 18;10:2040622319862714. doi: 10.1177/2040622319862714

Table 1.

Summary of the studies included in the meta-analysis.

First author year, country NOS (stars) Placebo group Sample matrix Assay type n Age mean or median (years) Sex (M/F) MDA before mean ±SD (μmol/l) MDA after mean ±SD (μmol/l) Disease Therapy type Therapy duration (weeks)
Zhang and colleagues26 Belgium 9 yes p Colorimetric 20 43 16/4 2.4±0.6 2.5±0.9 T1DM Pravastatin 20 mg/day 12
Nishikawa and colleagues27 Japan 8 no s NR 38 58.7 20/18 0.569±0.139 0.500±0.097 ESRD Simvastatin 5 mg/day 24
Chang and colleagues28 Korea 9 yes p Colorimetric 31 63 8/23 3.15±1.27 3.47±1.17 ESRD Simvastatin 20 mg/day 8
Harangi and colleagues29 Hungary 8 no s Colorimetric 13 53.6 4/9 1.00±0.26 0.79±0.20 Hyperlipidaemia Atorvastatin 10 mg/day 52
Koh and colleagues31
South Korea		 9 yes p ELISA 32 62 13/19 1.94±0.71 1.58±0.75 CAD Simvastatin 20 mg/day + diet 14
Kural and colleagues32 Turkey 8 no s Colorimetric 40 53.5 21/19 5.96±2.25 3.81±1.00 Hypercholesterolemia and hyperlipidaemia Atorvastatin 10 mg/day 10
Koh and colleagues30 South Korea 8 no p ELISA 50 59 22/28 1.36±0.57 1.17±0.49 Hypercholesterolaemia Simvastatin 20 mg/day 8
Koh and colleagues30 South Korea 8 no p ELISA 50 59 22/28 1.45±0.64 1.01±0.49 Hypercholesterolaemia Simvastatin 20 mg/day + ramipril 10 mg/day 8
Manuel-y-Keenoy and colleagues33 Belgium 8 no p Colorimetric 11 59 9/2 1.17±0.31 0.80±0.21 T1DM Atorvastatin 20 mg/day 26
Manuel-y-Keenoy and colleagues33 Belgium 8 no p Colorimetric 11 59 10/1 1.27±0.39 0.79±0.16 T1DM Atorvastatin 20 mg/day + α-tocopherol 750 IU 26
Skrha 200434 Czech Republic 8 no p Colorimetric 20 57 12/8 2.56±0.45 2.39±0.50 T2DM Simvastatin 20 mg/day 12
Karatzis and colleagues35 Greece 9 yes s Colorimetric 20 62.1 20/0 3.89±1.99 2.67±1.30 Unstable angina Pravastatin 40 mg/day 1.5
Save and colleagues36 India 8 no s Colorimetric 100 51.3 29/71 6.5±1.1 5.3±0.9 Hyperlipidaemia T2DM Atorvastatin 10 mg/day 24
Molcányiová and colleagues39 Slovakia 8 no p Colorimetric 42 42 12/30 2.00±0.48 1.88±0.44 Hypercholesterolaemia Simvastatin 20 mg/day 8
Koh and colleagues38 South Korea 8 no p ELISA 50 59 30/20 0.85±0.41 0.72±0.31 T2DM Simvastatin 20 mg/day 8
Koh and colleagues38 South Korea 8 no p ELISA 50 59 30/20 0.83±0.36 0.60±0.31 T2DM Simvastatin 20 mg/day + ramipril 10 mg/day 8
Abou-Raya and colleagues37 Egypt 9 yes p NR 20 59.8 5/15 5.95±3.70 4.91±3.50 SSc Atorvastatin 40 mg/day 26
Castro and colleagues40 Chile 9 yes P Colorimetric 38 58 31/7 1.18±0.43 1.03±0.43 CHF Atorvastatin 20 mg/day 8
Usharani and colleagues41 India 9 yes s Colorimetric 23 50 12/11 3.46±0.51 2.16±0.17 T2DM Atorvastatin 10 mg/day 8
Nagila and colleagues42 Thailand 8 no s Colorimetric 22 57.7 NR 17.6±2.7 14.8±2.9 Hypercholesterolaemia Atorvastatin 10 mg/day 3
Abdin and colleagues15 Egypt 8 no s Colorimetric 22 35–75 NR 7.65±3.64 4.75±2.30 T2DM Atorvastatin 10/20 mg/day 12
Li and colleagues43 China 8 no p Colorimetric 80 54 45/35 5.23±0.13 4.06±0.14 CAD Simvastatin 20 mg/day 12
Li and colleagues43 8 no p Colorimetric 84 56 51/33 5.42±0.15 3.82±0.12 CAD Atorvastatin 10 mg/day 12
Su and colleagues44 China 8 no p HPLC 75 55 39/36 8.01±0.73 4.49±0.58 T2DM Simvastatin 40 mg/day 12
Su and colleagues44 China 8 no p HPLC 76 56 43/33 8.04±0.93 4.22±0.45 T2DM Atorvastatin 10 mg/day 12
El-Barbary and colleagues45 Egypt 8 no s Colorimetric 15 54.8 3/12 4.42±0.81 2.25±0.32 RA Atorvastatin 40 mg/day
+ prednisone 10 mg/day + MTX 0.2 mg/kg/week		 26
Koh and colleagues46 South Korea 9 yes p ELISA 42 53 22/20 1.26±0.45 1.07±0.32 Hypertension Atorvastatin 20 mg/day 8
Koh and colleagues46 South Korea 8 yes p ELISA 42 53 22/20 1.30±0.45 1.02±0.32 Hypertension Atorvastatin 20 mg/day + amlodipine 10 mg/day 8
Samy and colleagues47 Egypt 9 no s Colori-metric 25 35–62 11/14 3.03±0.23 2.77±0.41 NAFLD Atorvastatin 40 mg/day 34
Sathyapalan and colleagues48 United Kingdom 8 yes s HPLC 19 26.6 NR 0.29±0.04 0.23±0.03 PCOS Atorvastatin 20 mg/day 12
Lazich and colleagues49 USA 8 no s ELISA 20 55.1 14/6 8.48±2.89§ 7.21±2.35§ Metabolic syndrome Simvastatin 40 mg/day 26
Lazich and colleagues49 USA 8 no s ELISA 23 58.7 9/14 9.22±2.01§ 7.00±2.72§ Metabolic syndrome Simvastatin 40 mg/day + rosiglitazone 4 mg/day 26
Zinellu and colleagues51 Italy 8 no p CE 10 63 8/2 0.248±0.095 0.220±0.129 CKD (III–IV) Simvastatin 40 mg/day 52
Zinellu and colleagues51 Italy 8 no p CE 20 59 14/6 0.203±0.163 0.154±0.118 CKD (III–IV) Simvastatin 20–40 mg/day + ezetimibe 10 mg/day 52
Murrow and colleagues50 USA 8 no p Colorimetric 17 54.2 8/9 3.7±1.5 2.1±0.8 Hyperlipidaemia metabolic syndrome T2DM Atorvastatin 10 mg/day 12
Murrow and colleagues50 USA 8 no p Colorimetric 19 51.4 5/14 3.1±1.0 2.5±1.0 Hyperlipidaemia metabolic syndrome T2DM Pravastatin 80 mg/day 12
Andrade and colleagues52 Brazil 9 no p Colorimetric 25 19–58 0/25 16.0±9.8§ 9.5±4.1§ Obesity Simvastatin 20 mg/day 6.5
Scheffer and colleagues53 Netherlands 8 no p HPLC 12 40 6/6 7.7±3.3 8.4±3.1 T1DM or T2DM obesity hypertension Atorvastatin 10 mg/day 12
Scheffer and colleagues53 Netherlands 8 no p HPLC 18 45.3 6/12 7.6±2.8 7.1±2.8 T1DM or T2DM obesity hypertension Simvastatin 40 mg/day 12
Villela and colleagues54 Brazil 8 no p Colorimetric 25 19–58 0/25 12.3±0.9 8.5±0.7 Obesity Simvastatin 20 mg/day 6
Çiftçi and colleagues55 Turkey 8 no p HPLC 30 40–60 10/20 0.09±0.02 0.06±0.03 Hypercholesterolaemia Atorvastatin 10 mg/day 12
Mirjanic-Azaric and colleagues56 Slovenia 8 no p HPLC 44 61.5 12/32 1.39±0.34 1.68±0.51 Stable angina Atorvastatin 20 mg/day 10
Villegas-Rivera and colleagues57 Mexico 9 yes p Colorimetric 25 55 10/15 0.99±0.75 0.52±0.50 T2DM Simvastatin 20 mg/day + ezetimibe 10 mg/day 16
Villegas-Rivera and colleagues57 Mexico 9 yes p Colorimetric 25 54 12/13 0.82±0.75 0.53±0.50 T2DM Rosuvastatin 20 mg/day 16
Yildiz and colleagues58 Turkey 8 no s HPLC 18 38.3 9/9 2.83±0.22 1.10±0.39 Kidney transplant Fluvastatin 80 mg/day 4
Rasmussen and colleagues59 Denmark 9 yes p HPLC 20 25.2 20/0 0.160±0.042 0.160±0.041 Healthy Simvastatin 40 mg/day 2

CAD, coronary artery disease; CE, capillary electrophoresis; CHF, congestive heart failure; CKD, chronic kidney disease; ELISA, enzyme-linked immunosorbent assay; ESRD, end-stage renal disease; F, female; HPLC, high-performance liquid chromatography; NOS, Newcastle–Ottawa quality assessment scale for case-control studies; M, male; MDA, malondialdehyde; MTX, methotrexate; NAFLD, nonalcoholic fatty liver disease; NR, not reported; PCOS, polycystic ovary syndrome; RA, rheumatoid arthritis; SD, standard deviation; SSc, systemic sclerosis; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.

§

nmol/l.